Robert Frank
Adult Health · Brandon, WINPI 1447666870
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,105, more than ten times the $92 reported in 2021. Among adult health clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$718
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$483
- Otsuka America Pharmaceutical, Inc.$480
- Neurocrine Biosciences, Inc.$476
- Alkermes, Inc.$366
- Lundbeck LLC$297
- plus $909 from 9 others
What the payments were for
- Food & beverage$3,67999%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $718 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $483 |
| Otsuka America Pharmaceutical, Inc. | 41 | $480 |
| Neurocrine Biosciences, Inc. | 24 | $476 |
| Alkermes, Inc. | 20 | $366 |
| Lundbeck LLC | 20 | $297 |
| Vanda Pharmaceuticals Inc. | 15 | $218 |
| E.r. Squibb & Sons, L.L.C. | 5 | $214 |
| Corium, LLC | 11 | $149 |
| Axsome Therapeutics, Inc. | 6 | $111 |
| Indivior Inc. | 5 | $74 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Lilly USA, LLC | 1 | $21 |
| USWM, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,728 in reported general payments places this provider in the 90th percentile of 170 adult health providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 65 | $349,395 |
| Invega SustennaPaliperidone Palmitate | 14 | $50,126 |
| RexultiBrexpiprazole | 44 | $34,028 |
| VraylarCariprazine Hcl | 21 | $28,237 |
| CaplytaLumateperone Tosylate | 26 | $21,553 |
| Clozapine | 260 | $17,925 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $16,232 |
| Chlorpromazine Hcl | 27 | $16,000 |
| TrintellixVortioxetine Hydrobromide | 20 | $9,452 |
| Fluphenazine Hcl | 20 | $9,164 |
| Quetiapine Fumarate | 212 | $6,099 |
| Divalproex Sodium | 75 | $5,727 |
| Duloxetine Hcl | 99 | $5,336 |
| BelsomraSuvorexant | 29 | $5,147 |
| Paliperidone ErPaliperidone | 12 | $4,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $476 | $349,39565 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $480 | $34,02844 claims |
| AbbVieVraylar | $718 | $28,23721 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $483 | $21,55326 claims |
| Alkermes, Inc.Lybalvi | $366 | $16,23221 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $40 | $9,45220 claims |
| Lilly USA, LLCOlanzapine | $21 | $2,56583 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $66 | $74813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 170 adult health providers in Wisconsin.
Other adult health in Brandon
- Dawn SagrilloWhitefish Bay$247K
- Lindsey SimpsonMuskego$67K
- Winsome PantonMilwaukee$46K
- Anatoliy VelikodanovMilwaukee$10K
- Tatjana StevanovicWest Allis$10K
- Annike CollinsMilwaukee$9K
- Kristine TwomeyNeenah$5K
- Kay ConradtAppleton$4K
- Nicole RosinMilwaukee$4K
- Kaylan FentonMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.